The University of Pretoria is a multi-campus public research university in Pretoria, the administrative and de facto capital of South Africa.

During the past decade, University of Pretoria conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 11 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 8 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Pretoria" #1 sponsor was "National Cancer Institute (NCI)" with 7 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 1 trials sponsored and "International Atomic Energy Agency" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Pretoria" #1 collaborator was "Cancer and Leukemia Group B" with 3 trials as a collaborator, "Incyte Corporation" with 3 trials as a collaborator, "Canadian Cancer Trials Group" with 2 trials as a collaborator, "Eastern Cooperative Oncology Group" with 2 trials as a collaborator and "North Central Cancer Treatment Group" with 2 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "University of Pretoria" are "Breast Adenocarcinoma" (3 trials), "HER2/Neu Negative" (2 trials), "Stage IIIA Breast Cancer AJCC v7" (2 trials), "Systemic Lupus Erythematosus" (2 trials) and "Carcinoma, Non-small-cell Lung" (1 trials). Many other conditions were trialed in "University of Pretoria" in a lesser frequency.

Most popular intervention types in "University of Pretoria" are "Drug" (17 trials), "Biological" (6 trials), "Other" (6 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (5 trials), "Bevacizumab" (4 trials), "Cisplatin" (4 trials), "Baricitinib" (3 trials) and "Capecitabine" (2 trials). Other intervention names were less common.

The vast majority of trials in "University of Pretoria" are 18 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "University of Pretoria". undefined are not yet recruiting, 1 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in University of Pretoria, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in University of Pretoria, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".

University of Pretoria has several departments that took part in Clinical trials: "University of Pretoria Clinical Research Unit" - 11 trials, "University of Pretoria; Department of Medical Oncology" - 10 trials, "Steve Biko Academic Hospital; Oncology" - 7 trials